Synowledge Announces Record Growth in 2011; Anticipates Sustained Progress in 2012

Share |

Synowledge is a global provider of drug safety, regulatory affairs and related IT solutions to small, mid and large sized pharmaceutical and biotechnology companies.

Stamford, CT (I-Newswire) January 19, 2012 - Stamford, CT – Synowledge, LLC, a market leader in pharmacovigilance, regulatory affairs, and related IT services for pharmaceutical, medical device, and biotechnology companies, is pleased to announce 2011 as a year of record growth, with plans to continue the momentum into 2012.

In 2011, Synowledge added over 15 clients to its list of global clientele, including key multi-year case processing partnerships with a Top 5 Biotech and a Top 25 Pharma. With a volume of over 60,000 serious and non-serious adverse events processed in 2011, Synowledge’s case volumes have increased significantly and Synowledge forecasts that this growth will continue in 2012. In addition to the increased case volumes, Synowledge has advanced its aggregate reporting, signal detection, literature search, and safety system maintenance services.

As a result of significant aggregate growth, Synowledge announced the May 2011 opening of Synowledge GmbH in Frankfurt, Germany to strengthen its European project management and sales functions. Additionally, Synowledge opened a state of the art delivery & training campus in Mysore, India in October 2011. The Mysore facility provides augmented delivery functions and offers full business continuity for drug safety and IT activities at Synowledge’s Bangalore Delivery Center. Moving into 2012, Synowledge has also announced plans to open an office in Japan to better serve the Asia-Pacific market.

“The combination of expanded partnerships with industry leaders, steady growth in various areas of drug safety, and our extension into regulatory affairs services solidified Synowledge’s position as a market leader in 2011,” says David Ingraham, Director of Strategic Accounts. “With a growing network of offices and facilities spanning three continents and clients across the globe, we are confident that 2012 will be another year of significant progress. We look forward to expanding our global footprint by continuing to provide life sciences companies with value added services that increase efficiency, productivity, and compliance with regulatory agencies, while significantly reducing costs.”





About Synowledge LLC:
Synowledge is a global provider of drug safety, regulatory affairs and related IT solutions to small, mid and large sized pharmaceutical and biotechnology companies. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet our clients’ needs. With more than 15 years of industry experience, our core team members have worked with leading pharmaceutical, biotech, medical device, and health care provider organizations. Synowledge is headquartered in Stamford, CT, USA with operation facilities located in Ohio, the United Kingdom, Germany, and India. For more information, please visit http://www.synowledge.com.

Company Contact Information
Synowledge LLC
David Ingraham
2777 Summer Street, 6th floor, Stamford, CT
06905
Phone : 203-504-2561




Science and Research

Regulatoryaffairs   regulatoryaffair   regulatoryaffairsconsultant  

January 19, 2012

Content Disclaimer: If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service company and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter,make sure to check the official company website for accurate release dates as our site displays the date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.


Related Releases

Sol Solar Announces Breakthrough In Its Graphene Solar Cells.
Sol Solar Power Co., Ltd. is a world-leading manufacturer of high-performance solar power products. The company sells its products to solar manufacturers worldwide, who assemble and integrate solar cells into modules and systems that convert sunlight

Book Launch: Much-Anticipated Memoir of Geoffrey Notkin, Star of TV’s “Meteorite Men,” Out June 1
"Rock Star: Adventures of a Meteorite Man" Available NOW For Advanced Orders and Media Review Copies

20 High School Students to Participate in USA Biology Olympiad at Purdue University
The USA Biology Olympiad concentrates on stimulating young scholars’ intellectual curiosity and developing their critical thinking skills in biological reasoning, and culminates with the U.S. Team’s participation in the IBO.

Intellectual Property: From Creation to Commercialisation - New Book by John Mc Manus
Launched at NovaUCD, Dublin, and available in ePub and Kindle versions as well as hardback, Intellectual Property: From Creation to Commercialisation provides a detailed grounding for innovators and researchers.

Facebook Announces Tweaks on Policy Change
Facebook has announced another round of updates to previous drafts of its terms of service named Statements of Rights and Responsibilities in an attempt to ease concerns on information sharing and privacy.


© Copyright 2012 I-Newswire.com - press release distribution service. All rights reserved